 Conformis Inc NASDAQ: CFMS stock is down after the Q3 revenue update ahead of the Oppenheimer Fall Healthcare Life Sciences MedTech Summit. Related Link: Conformis Q2 Earnings Surpass Estimates On Higher Volumes And Royalties, License Revenue. 